A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF ZANZALINTINIB (XL092) IN COMBINATION WITH PEMBROLIZUMAB VS PEMBROLIZUMAB IN THE FIRST-LINE TREATMENT OF SUBJECTS WITH PD-L1 POSITIVE RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCIN
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Exelixis, Inc
Start Date
August 16, 2024
End Date
September 22, 2029
Administered By
Duke Cancer Institute
Awarded By
Exelixis, Inc
Start Date
August 16, 2024
End Date
September 22, 2029